30 closest matches · ranked by relevance
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Influenza
Primary: Quantification of Antibody Titers — 37.4; 24.6; 6.81 Antibody titer
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 6; 24; 21 Participants
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
Immunity to Influenza Vaccine
Primary: Cellular Immune Response — 0.239; 0.137; 0.243; 0.160 percentage of Stimulated cells
Influenza
Primary: Number of Subjects Shedding Vaccine Virus of Each Subtype by PCR — 1; 6; 9; 1 participants
Influenza
Primary: Number of Participants Who Received the Influenza Vaccine — 59; 37; 40 Participants
Influenza
Primary: Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years — 315; 581; 697; 1048…
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants
Influenza Vaccine
Primary: Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/17/Duck/Potsdam/86/92 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated…
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines. — 28.25…
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Healthy Volunteer
Primary: Microneutralization Titers — 0.769; 1.313; 1.716; 1.333 Log2 Fold Change
Influenza · Vaccine Virus Shedding
Primary: Number of Participants Shedding Each Vaccine Virus Measured by qPCR of Nasosorption Samples — 31 participants
2009 H1N1 Influenza Virus
Primary: Number of Participants Who Shed Virus — 0 participants
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres
Influenza A Subtype H5N1 Infection
Primary: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29 After Vaccination With the Seasonal…
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 20 Participants
Flu Vaccine
Primary: Hemagglutinin Antigen Inhibition Assay Titers at Baseline — 20; 160; 25; 40 antibody titers
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
Influenza
Primary: Microneutralization (MN) Assay Response to Cell-grown Influenza A/H3N2 - Seroconversion Rate (SCR) — 112; 48; 29 Participants
Influenza
Primary: Innate Cell IFNa2a Production — 112.3650; 131.4214; 107.5846; 134.9071 pg/mL
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 5; 5; 6; 3 Participants
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs